FINWIRES · TerminalLIVE
FINWIRES

$NMRA

4 stories mentioning NMRAUpdated 45d ago

Every FINWIRES story that references NMRA, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Monday afternoon with the NYSE Healthcare Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 0.6%.In corporate news, Centene (CNC) will offer buyouts to most employees to reduce costs after a slump in health-plan membership in the past year, Bloomberg reported. Centene shares fell 3.2%.Neumora Therapeutics (NMRA) shares tumbled 48% after the company halted development of its major depressive disorder treatment navacaprant after two Phase 3 trials failed to meet their primary and key secondary endpoints. Neumora also announced it will reduce its workforce by 35%.Elicio Therapeutics (ELTX) shares plunged 72% after the company said a Phase 2 study assessing the experimental pancreatic cancer therapy ELI-002 7p did not meet the prespecified primary endpoint of disease-free survival.Cuprina (CUPR) shares surged 102% after a subsidiary obtained 510(k) clearance from the US Food and Drug Administration for its Medifly Maggots product that uses Lucilia cuprina larvae in maggot debridement therapy.

$CNC$CUPR$ELTX$NMRA
Sectors

Sector Update: Healthcare Stocks Softer Monday Afternoon

Healthcare stocks declined Monday afternoon with the NYSE Healthcare Index dropping 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In sector news, the Centers for Medicare & Medicaid Services proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price-applicability year, shifting to codified regulations from implementation through annual guidance.In corporate news, Neumora Therapeutics (NMRA) shares tumbled 52% after the company halted development of its major depressive disorder treatment navacaprant after two Phase 3 trials failed to meet their primary and key secondary endpoints. Neumora also announced it will reduce its workforce by 35%.Elicio Therapeutics (ELTX) shares plunged 72% after the company said a Phase 2 study assessing the experimental pancreatic cancer therapy ELI-002 7p did not meet the prespecified primary endpoint of disease-free survival.Cuprina Holdings (CUPR) shares more than doubled after a subsidiary obtained 510(k) clearance from the US Food and Drug Administration for its Medifly Maggots product that uses Lucilia cuprina larvae in maggot debridement therapy.

$CUPR$ELTX$NMRA
Sectors

Sector Update: Healthcare

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, Neumora Therapeutics (NMRA) shares fell 48% after the firm said Monday it is discontinuing development of its major depressive disorder treatment navacaprant after two phase 3 trials failed to meet their primary and key secondary endpoints.

$NMRA
Wire

Neumora Halts Navacaprant Development After Phase 3 Depression Trials Miss Primary Endpoints; Shares Fall Pre-Bell

Neumora Therapeutics (NMRA) said Monday it is discontinuing development of its experimental major depressive disorder treatment navacaprant after two phase 3 studies failed to meet their primary and key secondary endpoints.The KOASTAL-2 and KOASTAL-3 trials, which enrolled more than 850 patients combined, did not show a statistically significant improvement over placebo on the Montgomery-Asberg Depression Rating Scale after six weeks of treatment.The company said pre-specified analyses of patients enrolled after study optimizations in early 2025 also failed to demonstrate efficacy.Following the setback, Neumora announced plans to reduce its workforce by about 35%, a move expected to generate annualized cost savings of roughly $10 million.The company said it expects existing cash reserves to fund operations into Q3 of 2027.Shares of Neumora fell more than 51% in recent premarket activity Monday.Price: $0.86, Change: $-0.91, Percent Change: -51.40%

$NMRA

Track with the FINWIRES app suite

NMRA News | FINWIRES